Biomedical Engineering Reference
In-Depth Information
[55] Abes R, Arzumanov AA, Moulton HM, Abes S, Ivanova GD, Iversen PL, et al. Cell-pen-
etrating-peptide-based delivery of oligonucleotides: an overview. Biochem Soc Trans
2007;35:775-9.
[56] Harding JA, Engbers CM, Newman MS, Goldstein NI, Zalipsky S. Immunogenicity and
pharmacokinetic attributes of poly(ethylene glycol)-grafted immunoliposomes. Biochim
Biophys Acta 1997;1327:181-92.
[57] Zabner J, Fasbender AJ, Moninger T, Poellinger KA, Welsh MJ. Cellular and molecular
barriers to gene transfer by a cationic lipid. J Biol Chem 1995;270:18997-9007.
[58] Lechardeur D, Lukacs GL. Intracellular barriers to non-viral gene transfer. Curr Gene
Ther 2002;2:183-94.
[59] Lima MC, Simões S, Pires P, Gaspar R, Slepushkin V, Duzgunes N. Gene delivery medi-
ated by cationic liposomes: from biophysical aspects to enhancement of transfection. Mol
Membr Biol 1999;16:103-9.
[60] Pereira FB, Goni FM, Nieva J. Liposome destabilization induced by the HIV-1 fusion
peptide Effect of a single amino acid substitution. FEBS Lett 1995;362:243-6.
[61] Kaneda Y, Uchida T, Kim J, Ishiura M, Okada Y. The improved efficient method for
introducing macromolecules into cells using HVJ (Sendai virus) liposomes with ganglio-
sides. Exp Cell Res 1987;173:56-69.
[62] Farhood H, Serbina N, Huang L. The role of dioleoyl phosphatidylethanolamine in cat-
ionic liposome mediated gene transfer. Biochim Biophys Acta 1995;1235:289-95.
[63] Litzinger DC, Huang L. Phosphatidylethanolamine liposomes: drug delivery, gene trans-
fer and immunodiagnostic applications. Biochim Biophys Acta 1992;1113:201-27.
[64] Boussif O, Lezoualc'h F, Zanta MA, Mergny MD, Scherman D, Demeneix B, et al.
A versatile vector for gene and oligonucleotide transfer into cells in culture and
in vivo
:
polyethylenimine. Proc Natl Acad Sci USA 1995;92:7297-301.
[65] Remy JS, Sirlin C, Vierling P, Behr JP. Gene transfer with a series of lipophilic DNA-
binding molecules. Bioconjug Chem 1994;5:647-54.
[66] Xu Y, Szoka Jr FC. Mechanism of DNA release from cationic liposome/DNA complexes
used in cell transfection. Biochemistry 1996;35:5616-23.
[67] Johnson-Saliba M, Jans DA. Gene therapy: optimising DNA delivery to the nucleus. Curr
Drug Targets 2001;2:371-99.
[68] Jere D, Arote R, Jiang HL, Kim YK, Cho MH, Cho CS. Bioreducible polymers for effi-
cient gene and siRNA delivery. Biomed Mater 2009;20:1-4.
[69] Wang CY, Huang L. Highly efficient DNA delivery mediated by pH-sensitive immunoli-
posomes. Biochemistry 1989;28:9508-14.
[70] Shockett PE, Schatz DG. Diverse strategies for tetracycline-regulated inducible gene
expression. Proc Natl Acad Sci USA 1996;93:5173-6.
[71] Medzhitov R, Janeway Jr C. Innate immune recognition: mechanisms and pathways.
Immunol Rev 2000;173:89-97.
[72] Varga LV, Toth S, Novak I, Falus A. Antisense strategies: functions and applications in
immunology. Immunol Lett 1999;69:217-24.
[73] Walder RY, Walder JA. Role of RNase H in hybrid-arrested translation by antisense oli-
gonucleotides. Proc Natl Acad Sci USA 1988;85:5011-15.
[74] Crum C, Johnson JD, Nelson A, Roth D. Complementary oligodeoxynucleotide mediated inhi-
bition of tobacco mosaic virus RNA translation
in vitro
. Nucleic Acids Res 1988;16:4569-81.
[75] Kawasaki AM, Casper MD, Freier SM, Lesnik EA, Zounes MC, Cummins LL, et al.
Uniformly modified 2-deoxy-2-fluoro-phosphorothioate oligonucleotides as nuclease-resis-
tant antisense compounds with high affinity and specificity for RNA targets. J Med Chem
1993;36:831-41.
Search WWH ::
Custom Search